In our study, SGSS05-NS3 compound had a highly significant In Vitro Therapeutic Index (IVTI) across several NB cell lines and non-transformed cells, with enhanced activity at reactivating p53 functions and increasing p53 total protein levels in both MYCN-WT and amplified NB cells, supporting the use of this drug in a broad range of HR-NBs. This evidence concerns the gene KRAS and neuroblastoma.